Plus Therapeutics (PSTV) Enterprise Value (2016 - 2025)
Plus Therapeutics (PSTV) has disclosed Enterprise Value for 16 consecutive years, with -$16.6 million as the latest value for Q3 2025.
- On a quarterly basis, Enterprise Value fell 246.72% to -$16.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$16.6 million, a 246.72% decrease, with the full-year FY2024 number at -$3.6 million, up 57.84% from a year prior.
- Enterprise Value was -$16.6 million for Q3 2025 at Plus Therapeutics, down from -$6.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$397000.0 in Q1 2024 to a low of -$21.3 million in Q3 2021.
- A 5-year average of -$12.5 million and a median of -$11.9 million in 2023 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: surged 96.88% in 2024, then plummeted 2385.39% in 2025.
- Plus Therapeutics' Enterprise Value stood at -$21.3 million in 2021, then rose by 14.85% to -$18.1 million in 2022, then skyrocketed by 52.79% to -$8.6 million in 2023, then skyrocketed by 57.84% to -$3.6 million in 2024, then plummeted by 360.37% to -$16.6 million in 2025.
- Per Business Quant, the three most recent readings for PSTV's Enterprise Value are -$16.6 million (Q3 2025), -$6.9 million (Q2 2025), and -$9.9 million (Q1 2025).